T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Warner Bros
WBD
$69.6B
| $49.1M | 0.01% |
4,265,787
-176,700
| -4% | -$2.4M |
|
652
Freshpet
FRPT
$3.5B
| $49M | 0.01% |
977,756
-1,470,487
| -60% | -$69.3M |
|
653
Primerica
PRI
$9.62B
| $49M | 0.01% |
396,620
-48,202
| -11% | -$6.11M |
|
654
SM Energy
SM
$7.71B
| $48.9M | 0.01% |
1,299,936
+331,890
| +34% | +$13.1M |
|
|
HZNP
655
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $48.9M | 0.01% |
789,755
-1,616
| -0.2% | -$113K |
|
656
Performance Food Group
PFGC
$16.4B
| $48.6M | 0.01% |
1,131,683
+83,082
| +8% | +$4.11M |
|
|
NARI
657
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $48.2M | 0.01% |
663,048
-1,303,254
| -66% | -$97M |
|
658
Zentalis Pharmaceuticals
ZNTL
$297M
| $48M | 0.01% |
2,217,740
-2,080,811
| -48% | -$56.9M |
|
659
Boyd Gaming
BYD
$6.05B
| $48M | 0.01% |
1,006,837
+4,870
| +0.5% | +$261K |
|
660
Scholar Rock
SRRK
$6.46B
| $47.9M | 0.01% |
6,908,142
-1,528,043
| -18% | -$12.7M |
|
661
Brookfield
BN
$111B
| $47.8M | 0.01% |
2,169,215
-1,055,479
| -33% | -$27.3M |
|
662
Aflac
AFL
$60.7B
| $47.8M | 0.01% |
850,504
-1,932
| -0.2% | -$114K |
|
663
Atkore
ATKR
$3.17B
| $47.7M | 0.01% |
613,228
+639
| +0.1% | +$55.2K |
|
664
Tenaris
TS
$26.6B
| $47.6M | 0.01% |
1,842,507
+1,781,007
| +2,896% | +$47.1M |
|
665
DuPont de Nemours
DD
$19.5B
| $47.5M | 0.01% |
750,102
-18,708
| -2% | -$1.33M |
|
666
Nurix Therapeutics
NRIX
$2.82B
| $47M | 0.01% |
3,606,352
-1,014,471
| -22% | -$16.1M |
|
667
Inspire Medical Systems
INSP
$1.68B
| $46.9M | 0.01% |
264,666
+25,737
| +11% | +$5.17M |
|
668
Entrada Therapeutics
TRDA
$290M
| $46.8M | 0.01% |
2,972,050
+534,552
| +22% | +$6.79M |
|
669
Deckers Outdoor
DECK
$12.7B
| $46.7M | 0.01% |
896,910
-4,527,954
| -83% | -$236M |
|
670
Zscaler
ZS
$30.4B
| $46.7M | 0.01% |
283,915
-3,942
| -1% | -$645K |
|
671
Curtiss-Wright
CW
$25.4B
| $46.6M | 0.01% |
335,098
+1,845
| +0.6% | +$262K |
|
672
Cboe Global Markets
CBOE
$30.6B
| $46.5M | 0.01% |
395,876
-4,567,174
| -92% | -$550M |
|
673
Aptiv
APTV
$10.2B
| $46.4M | 0.01% |
592,818
+1,686
| +0.3% | +$162K |
|
|
BLD
674
DELISTED
TopBuild
BLD
| $46.1M | 0.01% |
280,033
-21,314
| -7% | -$3.94M |
|
675
Realty Income
O
$59.6B
| $46M | 0.01% |
790,695
+14,601
| +2% | +$1.01M |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.